In vivo evaluation of (18)F-labeled TCO for pre-targeted PET imaging in the brain [0.03%]
TC0的(18) F标记物的体内评价用于脑部预靶向PET影像学检查
Leonie Wyffels,David Thomae,Ann-Marie Waldron et al.
Leonie Wyffels et al.
Introduction: The tetrazine-trans-cylooctene cycloaddition using radiolabeled tetrazine or radiolabeled trans-cyclooctene (TCO) has been reported to be a very fast, selective and bioorthogonal reaction that could be usefu...
Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β) [0.03%]
新型放射示踪剂[(11)C]PyrATP-1的合成及其用于葡萄糖合成酶激酶-3β((GSK-3β)的正电子发射断层扫描成像的研究
Erin L Cole,Xia Shao,Phillip Sherman et al.
Erin L Cole et al.
Introduction: The dysfunction of glycogen synthase kinase-3β (GSK-3β) has been implicated in a number of diseases, including Alzheimer's disease. The ability to non-invasively quantify GSK-3β activity in vivo is theref...
(99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor [0.03%]
针对EphA2受体的SWL特异性肽的(99m)Tc标记研究
Yu Liu,Xiaoli Lan,Tao Wu et al.
Yu Liu et al.
Introduction: EphA2, one member of the Eph receptor family, is widely expressed in multiple aggressive cancers. SWL, a small peptide identified by phage display, has high binding affinity to EphA2, suggesting that it coul...
Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (-)-[(18)F]Flubatine in humans [0.03%]
人受试者给药(-)-(18)F氟巴丁后血浆蛋白结合、代谢及其它生物参数的评价研究
Marianne Patt,Georg A Becker,Udo Grossmann et al.
Marianne Patt et al.
Introduction: (-)-[(18)F]Flubatine is a PET tracer with high affinity and selectivity for the nicotinic acetylcholine α4β2 receptor subtype. A clinical trial assessing the availability of this subtype of nAChRs was perf...
Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent [0.03%]
一种潜在的PET显像剂——uPA抑制剂的合成及其体内药效学评价研究
Johan Ides,David Thomae,Leonie Wyffels et al.
Johan Ides et al.
Introduction: The urokinase plasminogen activator (uPA) system is a proteolytic cascade involved in tumor invasion and metastasis. uPA and its inhibitor PAI-1 are described as biomarkers for breast cancer with the highest...
Gaurav Malviya,Alberto Signore
Gaurav Malviya
Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia [0.03%]
新型硫氧衍生物作为肿瘤低氧PET显像剂的标记及评价研究
Evelyn Laurens,Shinn Dee Yeoh,Angela Rigopoulos et al.
Evelyn Laurens et al.
[¹⁸F]FMISO is the most widely validated PET radiotracer for imaging hypoxic tissue. However, as a result of the pharmacokinetics of [¹⁸F]FMISO a 2h wait between tracer administration and patient scanning is required for optimal image ac...
Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy [0.03%]
载铜-213的CD138抗体药物偶联物与马法兰治疗多发性骨髓瘤的比较研究
S Gouard,A Pallardy,J Gaschet et al.
S Gouard et al.
Introduction: Multiple myeloma (MM) is a B-cell malignancy of terminally differentiated plasma cells within the bone marrow. Despite intense research to develop new treatments, cure is almost never achieved. Alpha-radioim...
Comparative Study
Nuclear medicine and biology. 2014 May:41 Suppl:e30-5. DOI:10.1016/j.nucmedbio.2014.02.008 2014
Whole-body biodistribution and dosimetry estimates of a novel radiotracer for imaging of serotonin 4 receptors in brain: [¹⁸F]MNI-698 [0.03%]
新型血清素受体放射示踪剂[¹⁸F]MNI-698的全身生物分布及剂量学研究
Adriana Alexandre S Tavares,Fabien Caillé,Olivier Barret et al.
Adriana Alexandre S Tavares et al.
Introduction: A new radiotracer for imaging the serotonin 4 receptors (5-HT4) in brain, [¹⁸F]MNI-698, was recently developed by our group. Evaluation in nonhuman primates indicates the novel radiotracer holds promise as...